Article PDF
References
Beales, J. Howard, III.1996. New Uses for Old Drugs. InCompetitive Strategies in the Pharmaceutical Industry, edited by R. B. Helms, 281–305. Washington, D.C.: American Enterprise Institute for Public Policy Research.
Mehlman, MJ [webpage on the Internet]. Off-label prescribing. New York, NY: interMDnet Corporation. [updated 2005 May; cited 9 May2006]. Available from: http://www. thedoctorwillseeyounow.com/articles/bioethics/offlabel_11.
Crofab [package insert]. Brentwood, TN: Protherics Inc; January2006.
Acetadote [package insert]. Nashville, TN: Cumberland Pharmaceuticals; February2006.
Roberts R, Rodriguez W, Murphy D, Crescenzi T. Pediatric drug labeling: Improving the safety and efficacy of pediatric therapies.JAMA 2003; 290: 905–911.
Hill P. Off license and off label prescribing in children: litigation fears for physicians.Arch Dis Child 2005; 90: i17-i18.
Specific requirements on content and format of labeling for human prescription drugs: revision of “pediatric use” subsection in the labeling,59 Federal Register 64240 (1994).
Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients,63 Federal Register 66631 (1998).
Federal Drug Administration [webpage on the Internet]. Approved active moieties to which FDA has granted pediatric exclusivity for pediatric studies under Section 505A of the Federal Food, Drug, and Cosmetic Act. Washington, D.C.: Federal Drug Administration [updated 23 March 2006; cited 9 May2006]. Available from: http://www.fda.gov/cder/pediatric/ exgrant.htm
Buckman Co. v. Plaintiffs’ Legal Comm. (98-1768) 531 U.S. 341 (2001);159 F.3d 817, reversed.
Center for Drug Evaluation and Research [webpage on the Internet]. Oncology Tools: A short tour. Washington, D.C.: Food and Drug Administration [update 17 January 2006; cited 9 May2006]. Available from: http://www.fda.gov/cder/cancer/tour.htm.
Accreditation Council for Continuing Medical Education [webpage on the Internet]. Ask ACCME. Standards for Commercial Support, 5: Content and Format Without Commercial Bias. ACCME [updated 2004; cited 9 May2006]. Available from: http://www.accme.org/index.cfm/fa/faq.detail/category_id/ 2ae7d7bc-3bf4-47fa-9cc7-b75b6466c277.cfm.
Federal Drug Administration [webpage on the Internet]. Docket 02N-0209 — Request for comment on first amendment issues, Comment number: EC-9. Federal Drug Administration [update 28 May 2002; cited 9 May2006]. Available from: http://www.fda.gov/ohrms/dockets/98fr/02N-0209-EC-9.html.
Richardson v. Miller, No M1997-00205-COA-R3-CV, 2000 WI. 1157246 (Tenn. Ct. App. 16 Aug.2000)
American Academy of Pediatrics Committee on Drugs. Uses of drugs not described in the package insert (off-label uses).Pediatrics 2002; 110: 181–183.
Femrite v. Abbott Northwestern Hospital, 568 N.W. 2d 535, 542 (Minn. Ct. App.1997).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tomaszewski, C. Off-label: Just what the doctor ordered. J. Med. Toxicol. 2, 87–88 (2006). https://doi.org/10.1007/BF03161014
Issue Date:
DOI: https://doi.org/10.1007/BF03161014